AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04906889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
Study NCT05299203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride tablets
Description: dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
Study NCT04569058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation
Description: Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
Study NCT06175715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: carotid endarterectomy under local or general anethesia
Study NCT06519760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-C1
Description: 68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg
Study NCT06216171 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Adaptive Radiotherapy
Study NCT06216171 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: image guided radiotherapy without online adaptation
Description: image guided radiotherapy without online adaptation
Study NCT06069856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Folic Acid Tablets with 60 mg of iron
Description: IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization
Study NCT06069856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplements with 60 mg of elemental iron
Description: MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
Study NCT05265065 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran - Standard Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose.
Study NCT05265065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran - Fractional Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose.
Study NCT05312411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-E2CAR_EGFRtv1
Description: Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)
Study NCT05312411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UB_TT170
Description: Bispecific small molecule adapter formulated with phosphate buffered saline
Study NCT05775848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBP-418 (ribitol)
Description: The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
Study NCT05775848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BBP-418 (ribitol)
Description: The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
Study NCT05775848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
Study NCT05775848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
Study NCT05735626 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Piperine 150μM + tDCS 2mA
Description: 2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
Study NCT05735626 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Piperine 1mM + tDCS 2mA
Description: 2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
Study NCT05735626 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capsaicin 10μM + tDCS 2mA
Description: 2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
Study NCT05535660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid panel
Description: fasting blood draw to examine concentrations of lipids in maternal blood during pregnancy
Study NCT05108844 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videocapsule endoscopy
Description: Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
Study NCT05108844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videocapsule endoscopy
Description: Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
Study NCT04576715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEaM Intervention
Description: Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~* Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~* Management based on current best practices (however, may have additional education from the provider training)~* Return to school letters~* Primary Care Follow Up
Study NCT04576715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Continue with CHOA current best practices for mTBI:~* No TEaM Provider training (but will be offered to all providers at end of study)~* Will not be trained on utilization and implementation of the concussion screening alert and eMR template
Study NCT04979845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
Study NCT04979845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video exercise
Description: Patients will receive video instructions for home based exercises
Study NCT04986124 — intervention group
Intervention type: OTHER
Intervention: treatment as usual
Description: No inervention. Treatment regime remains unchanged.
Study NCT05547906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCA101
Description: IV infusion Twice a Week, 8 times per each Cycle
Study NCT05038891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Cervical Exam
Description: Standard Digital Cervical Exam by an experienced OB provider
Study NCT05038891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal Ultrasound
Description: Self-administered transperineal ultrasound after instruction by a health care professional
Study NCT05038891 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal Ultrasound
Description: Self-administered transvaginal ultrasound after instruction by a health care professional
Study NCT05285800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Hyperbaric Bupivacaine
Description: In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
Study NCT05285800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Hyperbaric Bupivacaine
Description: In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
Study NCT04871971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g NUTRALYS®S85 Plus pea protein
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.
Study NCT04871971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g NUTRALYS®S85 Plus pea protein
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.
Study NCT04871971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g Whey protein concentrate
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.
Study NCT04871971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g Whey protein concentrate
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.
Study NCT04871971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 50 g Glucose
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose
Study NCT05901714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimetoran
Description: Specified dose on specified days
Study NCT05901714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Specified dose on specified days
Study NCT05901714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Specified dose on specified days
Study NCT06034834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging of perfusion
Description: Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
Study NCT05075096 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: No intervention observational study.
Study NCT06419634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986497
Description: Specified dose on specified days
Study NCT06195384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen mRNA Vaccine
Description: Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
Study NCT05438680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: The bovine colostrum ( trade name : baby steps sachets, 300mg )
Description: The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally.
Study NCT05438680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: distilled water with no bovine colostrum
Study NCT05837780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding device
Description: comparison between using conventionally and digitally constructed nasoalveolar molding devices
Study NCT05586451 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional High Load Resistance Exercise (HLRE)
Description: Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.
Study NCT05586451 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)
Description: Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
Study NCT05586451 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)
Description: Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
Study NCT05944237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0039732 Capsules
Description: HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.
Study NCT05944237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0039732 Capsules and atezolizumab infusion
Description: HTL0039732 Capsules will be administered orally on a QD schedule to fasted participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Cycle 1 will consist of HTL0039732 monotherapy. From Cycle 2 onwards, participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.
Study NCT06316791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
Study NCT04953949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NU-MAX®
Description: Topical Hemostat
Study NCT05070273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve conduction study
Description: NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~1. angle of the lower jaw (proximal point),~2. the area of the carotid triangle (distal point),~3. directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms.
Study NCT05070273 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation of hypoglossal nerve
Description: TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold.
Study NCT06103695 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tapinarof
Description: Add on Vtama (tapinarof) to biololgic therapy
Study NCT05418062 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and commitment therapy (ACT)
Description: 8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
Study NCT05418062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: 8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
Study NCT04820452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose IBI302
Description: Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
Study NCT04820452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose IBI302
Description: High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
Study NCT04820452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intraocular injection
Study NCT06346028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H4 deep rTMS coil and Brainsway stimulator system
Description: An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC.
Study NCT05640752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2019 ESC guideline-determined diagnostic strategy
Description: ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL \<15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
Study NCT05640752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2016 NICE guideline-determined diagnostic strategy
Description: For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
Study NCT06236412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education about the contents listed under each arm will be provided for the participants.
Study NCT06236412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education about the contents listed under each arm will be provided for the participants.
Study NCT06532968 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study NCT06532968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORION spinal lamina cover
Description: an artificial lamina coverage of the ORION spinal system